Genetics Testing Result
Based on your answers you are at a low risk for genetic mutations for prostate cancer. To get more information on genetic testing in prostate cancer please see the information on our genetic testing page.
Resources
Prostate Cancer Information
What is the prostate?
The prostate is a walnut-sized gland in men that is apart of the reproductive system. The prostate sits low in the pelvis, below the bladder, in front of the rectum and the prostate surrounds the urethra. The prostate makes seminal fluid, the liquid in sperm that protects, supports and helps transport sperm.
What is prostate cancer?
Prostate Cancer begins when normal cells in the prostate begin to change and grow uncontrollably. Some prostate cancers grow slowly and may not cause symptoms or problems for years while other prostate cancers are more aggressive and grow quicker, unfortunately, there is no way to predict how aggressive a cancer is before a biopsy.
Prostate cancer is the most commonly diagnosed, major cancer among all Americans. The incidence of prostate cancer increases with age. Some studies have shown an overall 2- to 3-fold increase in the risk of prostate cancer in men who have a history of this disease in their family. Family history is defined as prostate cancer in a brother, father, or an uncle. It is more significant if a family member was diagnosed with prostate cancer at a younger age (less than 60 years old). The incidence rate of prostate cancer is two times higher in African-American men than Caucasian men.
For more information about prostate cancer please visit Prostate Conditions Education Council's website at www.prostateconditions.org.
PSA Testing
Prostate Conditions Education Council (PCEC) recommends a baseline prostate health assessment, including prostate specific antigen (PSA) and digital rectal exam (DRE), for all men at 40 years of age is beneficial for risk satisfaction. Based on this initial baseline assessment, PCEC recommends that men establish a detection follow-up schedule as stated below.
- Men with a baseline PSA results greater than 1.5ng/ml or those with an abnormal DRE should be monitored and evaluated. If the baseline PSA result is below 1.5ng/ml men and the DRE is normal testing can be every five years except for:
- African-American men, those with a family history of prostate cancer, breast cancer, ovarian cancer, pancreatic cancer, presence of the BRCA gene, exposure to certain chemicals known to cause cancer or men over the age of 65 years. These men should be monitored more frequently.
*PCEC does not advocate for screenings if a man’s life expectancy is less than 10 years.
Additional Information:
PCEC believes that all men should be informed of the pros and cons of early detection, diagnosis and treatment of prostate cancer.
PCEC encourages men to undergo a complete Men’s Health Evaluation and encourages a men’s health assessment which includes testing for: Testosterone, Total Triglycerides, Total Cholesterol, HDL, LDL, Glucose, PSA and new prostate cancer genomic markers and imaging tools as they become available. Men should be educated on the importance of a wellness prevention program including diet, exercise and weight.
Early detection programs are valuable for men who may not otherwise have access to or visit a physician on a regular basis.
Men must understand that screening does not diagnose cancer. Also, early detection of prostate cancer may find a cancer that does not need aggressive treatment and that the treatment options for prostate cancer often cause serious and life altering side effects.
A PSA blood test does not only look for cancer but also for other prostate abnormalities like enlarged prostates or prostate infections. A PSA of 1.5ng/ml is often used as a prostate health indicator of an issue with your prostate and it may be worth talking with a urologist.
PCEC will continue to support the development of personalized medicine through new markers for all conditions including the diagnosis and prognosis of prostate cancer through education and the utilization of our serum biorepository.
Genetic Testing
Genetic testing involves examining your DNA, the chemical database that carries instructions for your body’s functions. By taking a sample of your blood, saliva or tissue genetic testing can reveal changes (mutations) in your genes. Genetic testing plays a vital role in determining the risk of developing certain diseases, help with screening decisions and sometimes help identify the best medical treatment.
Genetic testing is voluntary and and with most tests it has benefits and risks that should be considered prior to having the testing done. A geneticist or genetic counselor can help by providing information about the pros and cons of genetic testing including the health, social and emotional aspects.
Myriad Genetics: The Prostate Cancer Quiz
Who should have a genetic test for prostate cancer
Experts recommend that the following men consider genetic testing
- All men with prostate cancer from families meeting established testing or syndrome criteria for hereditary breast, ovarian or prostate cancers as well as lynch syndrome.
- Men who have two or more close blood relatives that have breast cancer, ovarian cancer, pancreatic cancer, prostate cancer or lynch syndrome.
- Men with metastatic castrate resistant prostate cancer should consider genetic testing.
- Men who have had tumor sequencing indicating mutations in cancer-risk genes may be recommended for germline genetic testing.
Why is genetic testing important for prostate cancer patients?
- Inherited genetic mutations exist in 12% of men with metastatic prostate cancer. The mutations are primarily in DNA repair genes such as BRCA1, BRCA2, and ATM.
- Having genetic testing may help you and your doctor make the best cancer screening and treatment plan for you. People who have a cancer gene mutation may need to start cancer screening earlier than usual, undergo screening more often, have additional screening for certain types of cancer and have a more aggressive treatment plan.
- Certain treatment options are available for men who have certain genetic mutations offering a more personalized treatment plan.
- Knowing if you have a cancer gene mutation can help your family members know if they may have a higher risk for certain cancers.
Germline versus Somatic Mutation
Germline Mutation
A germline mutation is an inherited mutation and can be passed from generation to generation. Cancer caused by a germline mutations is called inherited or hereditary cancer. More than 50 different hereditary cancer syndromes have been identified that can be passed from one generation to the next.
Somatic Mutation
Somatic mutations occur from damage to genes in an individual cell during a person’s life. Somatic mutations are not found in every cell in the body and they are not passed from parent to child. Somatic mutations may occur over time and change during the course of treatment.
Other Resources
There are many resources avaialble for men and their caregivers seeking additional information about prostate cancer or looking for support groups to talk to near you.
www.menshealtheducationcouncil.org
Consider Your Genetic Risk
To determine your genetic risk check any items that apply to you.
- Have you been diagnosed with advanced prostate cancer or cancer that has spread outside of the prostate?
- Have you been diagnosed with prostate cancer that is a Gleason score of 7 or greater?
- Do you have a family history of prostate cancer in a father, grandfather, uncle or brother?
- Do you have a close blood relative (Mother, Father, Brother, Sister) that has been diagnosed with ovarian cancer, breast cancer (when they were under 50 years old), Lynch Syndrome or pancreatic cancer?
- Have you been treated for prostate cancer with hormone therapies like Xtandi or Zytiga?
- Have you had the BRCA 1 or BRCA 2 mutation found on tumor profiling?
If you answered yes to any of the questions above, please talk to your doctor about genetic testing.
Prostate Cancer Markers Companies
Beckman Coulter
MDxHealth
Genomic Health
GenomeDx
Myriad
OPKO Health, Inc.
Clinical Trials
There are many ongoing prostate cancer marker studies happening around the world!
Registry to Measure the Impact of Adding Genomic Testing
Myriad Genetic Laboratories, Inc.
This is a prospective open registry to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer. Physicians will complete a series of questionnaires. Biopsy tissue will be tested using the Prolaris® genomic test and a relative cancer aggressiveness score will be shared with the physician and the patient.
Click Here for More Information
A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease (EFFECT)
Astellas Pharma Europe Ltd.
The purpose of this study is to investigate the effect of the study medication (Eligard®) on cancer markers (in the blood) of prostate cancer.
Homepage Featured
What are markers?
And, what can they tell me about my health?
Prostate cancer markers are making an impact on the world of prostate cancer by helping to individualize patient care in the early detection, diagnosis and treatment choices for prostate cancer. Through advanced science researchers from many different institutions and companies have developed a variety of tests that look at each persons genes or biomarkers and help to determine individual risk for having prostate cancer, the need for biopsies or repeat biopsies and often the best course of treatment.
Contact Us
The Prostate Cancer Markers site is hosted by Prostate Conditions Education Council. Visit our website at www.prostateconditions.org.
Prostate Conditions Education Council
7009 South Potomac Street, Suite 125
Centennial, CO 80112
303-316-4685 (phone)
866-477-6788 (toll free)
303-320-3835 (fax)
Email us at This email address is being protected from spambots. You need JavaScript enabled to view it.
About Us
The Prostate Cancer Biomarkers website is brought to you by
Prostate Conditions Education Council.
Prostate Conditions Education Council (PCEC) was founded in 1989, and is a non-profit 501-3c organization. A national organization committed to men’s health, PCEC is the nation’s leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives, as well as the medical community about prostate cancer prevalence, the importance of early detection, and available treatment options, as well as other men’s health issues. The Council – comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates – aims to conduct nation wide screenings for men and perform research that will aid in the detection and treatment of prostate conditions.
PCEC is not only the national leader in providing prostate cancer screenings for men in all stages of the disease; PCEC is also the national leader in increasing awareness and education on prostate disease. Our education and awareness campaigns include a wide variety of forums and have expansive reach.
PCEC is also very proud to be leading the nation in prostate cancer marker awareness and making these markers accessible to all men!
To learn more about Prostate Conditions Education Council please visit out website at www.prostateconditions.org.
Prostate Cancer Markers
Markers are making a significant impact on the diagnosis of prostate cancer! What is a prostate cancer marker? As defined by the National Cancer Institute, a marker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. It may also refer to mutations, changes, or patterns in a tumor's DNA. Doctors may use marker tests to learn if you have cancer. These tests can also help doctors to learn more about your cancer and help to plan treatment.
Contact Us:
Prostate Conditions Education Council
7208 S. Tucson Way, suite 230
Centennial, CO 80112
303-316-4685 (phone)
866-477-6788 (toll free)
303-320-3835 (fax)
Email us at This email address is being protected from spambots. You need JavaScript enabled to view it.